alexa Enlarged liver | Israel | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Recommended Journals

Relevant Topics

Enlarged Liver

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Enlarged liver

    Hepatomegaly is the condition of having an enlarged liver. It is a non-specific medical sign having many causes, which can broadly be broken down into infection, direct toxicity, hepatic tumours, or metabolic disorder. Often, hepatomegaly will present as an abdominal mass. Depending on the cause, it may sometimes present along with jaundice. An enlarged liver is one that's bigger than normal. The liver is a large, football-shaped organ found in the upper right portion of your abdomen. The medical term for enlarged liver is hepatomegaly (Enlarged liver) isn't a disease. It's a sign of an underlying problem, such as liver disease, congestive heart failure or cancer. Treatment for enlarged liver involves identifying and controlling the underlying cause of the condition

  • Enlarged liver

    An enlarged liver may not cause any symptoms. When enlarged liver occurs because of liver disease, it may be accompanied by: Abdominal pain, Fatigue, Nausea and vomiting, Yellowing of the skin and the whites of the eyes (jaundice). The prevalence of FLD in the general population ranges from 10% to 24% in various countries. However, the condition is observed in up to 75% of obese people, 35% of whom progressing to NAFLD, despite no evidence of excessive alcohol consumption. FLD is the most common cause of abnormal liver function tests in the United States. "Fatty livers occur in 33% of European-Americans, 45% of Hispanic-Americans, and 24% of African-Americans. It is difficult to estimate the exact prevalence of cirrhosis, as previously undiagnosed cirrhosis is often found at post-mortem. There are an estimated 30,000 people living with cirrhosis in the UK and at least 7,000 new cases being diagnosed each year.
  • Enlarged liver

    The number of people living with both alcoholic cirrhosis and non-alcohol-related cirrhosis seems to be rising. There is concern that there are growing levels of dangerous alcohol consumption in the UK which may lead to increased numbers of people with cirrhosis. An analysis in the Lancet showed that between 1960 and 2002, total recorded alcohol consumption in Britain doubled.[8] The same report showed that between 1987-1991, and 1997-2001, cirrhosis mortality in men in Scotland more than doubled (104% increase) and in England and Wales rose by over two thirds (69%). Mortality in women increased by almost half (46% in Scotland and 44% in England and Wales). Treatment for enlarged liver involves diagnosing and treating the underlying condition that's causing it.
  • Treatment will vary according to the underlying cause of hepatomegaly. For example, if cirrhosis is present, lifestyle and diet changes are recommended. Avoid drinking alcohol or eating salt; consult a physician before taking any type of medication or supplement since the diseased liver may not be able to process such substances. Leukemia is treated with chemotherapy. Inflammatory diseases such as sarcoidosis are treated with corticosteroids to reduce inflammation.

Expert PPTs

Speaker PPTs

  • Li Yu-Jung
    Intra-maxillary Drug delivery and Bio-sensing via Dental Implant and its considerations
    PPT Version | PDF Version
  • Nicolae Bacalbasa
    The benefits of surgery for breast cancer liver metastases – a single center experience
    PPT Version | PDF Version
  • Sitanshu Sekhar Lahiri
    A novel oral formulation for cancer therapy, loaded in a slow release matrix for targeted delivery
    PPT Version | PDF Version
  • Li-Chun Tsou
    PDF Version
  • Dipesh Shah
    Compatibility assessment of a model monoclonal antibody formulation in glass and in blow-fi ll-seal (BFS) plastic vial delivery formats
    PPT Version | PDF Version
  • Stephanie Ramos
    Enhanced Delivery of Dna-Based Vaccines and Immunotherapeutics through Next-Generation Electroporation Devices
    PPT Version | PDF Version
  • Nirmala Chauhan
    Modification of dietary fiber psyllium for use in oral insulin delivery
    PPT Version | PDF Version
  • Youngmi Jung
    TSG-6 induces liver regeneration by enhancing autophagy in mice with chronic liver damage
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Suoqin Tang
    Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo
    PPT Version | PDF Version
  • Arshad mahmood
    TRANSPORT OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS) ACROSS MUCUS AND CELLULAR INTERNALIZATION
    PPT Version | PDF Version
  • Wei Duan
    Cancer stem cells targeted delivery of siRNA to overcome induced chemoresistance
    PPT Version | PDF Version
  • Yung-Chih Kuo
    “Yung-Chih Kuo-National-Chung-Cheng-University-Republic-of-China-Targeting-delivery-of-etoposide-to-inhibit-the-growth-of-human-glioblastoma-multiforme-using-lactoferrin-and-folic-acid-grafted-poly(lactide-co-glycolide)-nanoparticles”
    PPT Version | PDF Version
  • Biplab Mishra
    Compression of hepatoduodenal ligament by sponges during perihepatic packing for liver trauma leading to difficult maneuvering of angiography catheter through common hepatic artery: ‘Mishra Phenomenon’
    PPT Version | PDF Version
  • Mukesh Kumar
    Membrane fusion mediated cytosolic drug delivery through scFv targeted Sendai viral envelopes
    PPT Version | PDF Version
  • Osama A Fekry
    Impact of nutritional modification on Egyptian patients with fatty liver combined with HCV
    PPT Version | PDF Version
  • In-Woo Park
    Role of HIV-1 Nefin acceleration of HCV-mediated liver disease progression
    PPT Version | PDF Version
  • Sevgi Gungor
    Micelles as nanosized carriers for skin delivery of drugs
    PPT Version | PDF Version
  • Eggehard Holler
    Biodegradable nanobrushes for drug delivery
    PPT Version | PDF Version
  • Ahmed Mohammed Ashshi
    The correlations of activins and follistatin with viral load, liver damage, Interleukin-6 and tumour necrosis factor-α in treatment naïve patients with chronic hepatitis C genotype 1 and 4: A case-control study
    PPT Version | PDF Version
  • Navneet Sharma
    Transdermal patches based on solid lipid nanoparticles of Metformin: Novel approach for drug delivery of Type 2 diabetes
    PPT Version | PDF Version
  • Erhabor Osaro
    CHALLENGES OF BLOOD TRANSFUSION SERVICE DELIVERY IN SUB SAHARAN AFRICA
    PPT Version | PDF Version
  • Joanna Trojanek
    Metalloproteinases and their inhibitors gene expression profiles in leukocytes of primary hypertension (PH), non-alcoholic fatty liver disease (NAFLD), and obese children
    PPT Version | PDF Version
  • Mark D Gorrell
    The protease fibroblast activation proteinas a biomarker and therapeutic target in cancer and chronic liver injury
    PPT Version | PDF Version
  • Jim Klostergaard
    Magnetic vectoring for drug delivery to tumors: Past, present and is there a future?
    PPT Version | PDF Version
  • Sree Harsha
    Optimization of particles size for lung specific drug delivery by way of microspheres
    PPT Version | PDF Version
  • Ruslan N. Grishanin
    Adeno-associated virus-mediated delivery of amyloid β antibody for treatment of age-related retinal degenerative diseases
    PPT Version | PDF Version
  • Mauro Comes Franchini
    Gold, silver magnesium and magnetic nanoparticles: Nanomedicine applications in drug delivery
    PPT Version | PDF Version
  • Niren Murthy
    In vivo delivery of transcription factors with chemically modified oligonucleotides
    PPT Version | PDF Version
  • Nguyen Linh Toan
    Molecular impacts of virus infections and genetic variants on the course of HBV-related liver diseases in Vietnam
    PPT Version | PDF Version
  • Farhad Ahmadi
    The effect of dietary zinc oxide nanoparticles on liver enzymes activity and some of blood parameters from hatch to 14 days of broiler age (1 to 14 days of age)
    PPT Version | PDF Version
  • Richard Addo
    Ocular Delivery of peptides and proteins
    PPT Version | PDF Version
  • Tao Wu
    The association between TCM syndromes and SCAP polymorphisms insubjects with non-alcoholic fatty liver disease
    PPT Version | PDF Version
  • Andrea Chisari
    Effect of protein malnutrition during gestation and lactation on the physiology and liver structure in adult life
    PPT Version | PDF Version
 

High Impact List of Articles

Conference Proceedings

adwords